Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK) from its SEC filings: 2025 revenue $184.4 million (+404% vs the year before), net margin -4%, free cash flow $44.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $184.4 million |
| Revenue growth | +404% |
| Net income | -$6.9 million |
| Net margin | -3.7% |
| Free cash flow | $44.9 million |
| Diluted EPS | $-0.12 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -32% |
| Cash | $110.0 million |
| Share count, 1 year | +18% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.